Verdict: Side-by-side breakdown using the Bull Rankings model. PGNY scored 67.0, ALHC scored 69.7 — ALHC leads.
Compare another set
PGNY
Progyny, Inc.
Healthcare Plans · Quality-Growth
67
$27.93 · $2.1B
fundamentals as of
Score gap
2.7
ALHC leads
ALHC
Alignment Healthcare, Inc.
Healthcare Plans · Quality-Growth
69.7
$7.54 · $1.6B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestPGNY30.4x
Fastest growthALHC+46.1%
Strongest balance sheetPGNY0.06
Highest qualityPGNY86 / 100
Largest discount to fair valueALHC-58%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
PGNY
stronger →← stronger
ALHC
86
Qualityreturns · margins · balance sheet
46
62
Growthrevenue & earnings expansion
98
57
Valuevaluation vs sector peers
76
ALHC is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
PGNY
ALHC
$178mC
FCF
$178mC
+5.5%C+
Rev
+46.1%A
0.06A-
D/E
1.25C
30.4xB
P/E
47.2xC
2.69C
PEG
0.75A-
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
PGNY
ALHC
30% below
Price vs fair valuelower is cheaper
58% below
~-1%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~-6%/yr
+30%
1-yr DCF upside
+83%
+43%
5-yr DCF upside
+137%
+65%
10-yr DCF upside
+246%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
PGNY
Why this score
Buying back stock
Durable high returns
ALHC
Why this score
Diluting shareholders
The companies
PGNYProgyny, Inc.
Healthcare Plans · $27.93 · beta 1.02
Why now
Healthcare Plans · market cap $2.1b. 16% off the 52-week high of $33.06. 12 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $34.42 (implying +23% upside).
Moat
ROE 17% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income, mostly because of stock-based pay ($107m) — a real cost to shareholders, paid in shares rather than cash.
Risk
Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
ALHCAlignment Healthcare, Inc.
Healthcare Plans · $7.54 · beta 1.14
Why now
Healthcare Plans · market cap $1.6b. Down 70% from 52-week high of $25.12 — deep drawdown territory. Revenue growing +46% — in hypergrowth territory. PEG 0.75 — paying under fair value for the growth rate. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $17.15 (implying +127% upside).
Moat
ROE 20% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income.
Risk
Down 70% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 47x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Net margin 0.9% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where PGNY and ALHC diverge
On the headline score the gap is 2.7 points in favor of ALHC. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
QualityPGNY 86.1 · ALHC 45.6PGNY +40.5
GrowthPGNY 61.7 · ALHC 97.7ALHC +36.0
ValuePGNY 56.5 · ALHC 75.9ALHC +19.4
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is ALHC or PGNY the better stock?
ALHC scores higher: ALHC 69.7, PGNY 67.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do ALHC and PGNY differ most?
The widest gap is quality, where PGNY leads by 41 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.
How are ALHC and PGNY scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.